The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 103.00
Bid: 102.00
Ask: 104.00
Change: 0.00 (0.00%)
Spread: 2.00 (1.961%)
Open: 103.00
High: 103.00
Low: 103.00
Prev. Close: 103.00
DXRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Head of Global Data

8 Aug 2019 07:00

RNS Number : 3016I
Diaceutics PLC
08 August 2019
 

 

Diaceutics PLC

("Diaceutics" or the "Company")

 

Appointment of Head of Global Data

 

Diaceutics PLC, (AIM: DXRX), a provider of data analytics and implementation services to the global pharmaceutical industry, announces that it has appointed Derek Hosty as Head of Global Data with immediate effect. Derek will lead Diaceutics' data team as it helps more patients across the world access precision medicine drugs by driving better diagnostic testing through unique data insights.

 

Diaceutics analyses significant volumes of data from worldwide clinical laboratories conducting diagnostic tests that determine which patients are eligible for specific precision medicine drugs. The resulting insights are presented to pharmaceutical companies, who then use the information to reach more patients.

 

Bringing almost 20 years of experience in software, analytics and product development to the role, Derek will be responsible for spearheading the Company's data strategy and the software tools to support it, with an aim to give more patients the best possible outcome. In doing so, Derek will drive further use of machine learning and AI solutions that predict gaps in diagnostic care. He will also lead the global data team in providing accurate, secure and prompt insights that will result in better precision medicine decisions.

 

Prior to this new role in Diaceutics, Derek was General Manager for Cloud and Data at Irish software provider Openet, with a focus on addressing specific business problems with analytics and machine learning. He was also Director of Technology Strategy for Data and Analytics at Norwegian telecommunications provider, Telenor Group, with a principal focus on contextual marketing, data privacy and security.

 

Ryan Keeling, Chief Innovation Officer, Diaceutics, said: "We are leveraging the power of data to help break the industry mould so that more people get access to potentially life-saving new drugs. Our global data lake is expanding all the time and we are constantly innovating to ensure we are using and analysing that data in the most transformative way.

 

"Derek has a long track record of leading data & analytics initiatives to achieve specific business goals. His broad knowledge of software and machine learning will be crucial to ensuring we consistently deliver game-changing insights that transform patient healthcare."

 

Derek Hosty, Head of Global Data, Diaceutics, said: "Precision medicine is one of the most exciting developments in healthcare to date. However, it's not as effective as it should be because of low testing rates, slow test turnaround times and inconsistent results. Diaceutics realised early on that data can effect change and I look forward to using my experience to help Diaceutics achieve its mission to deliver seamless patient testing globally."

 

Enquiries:

 

Diaceutics PLC

www.diaceutics.com

Peter Keeling, Chief Executive Officer

via Walbrook PR

Philip White, Chief Financial Officer

 

 

 

Cenkos Securities plc (Nominated adviser and broker)

+44 (0) 20 3861 6630

Callum Davidson / Giles Balleny

 

Michael Johnson (Sales)

 

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893

 

 

 

 

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAUGUPARUPBGCM
Date   Source Headline
13th Mar 20237:00 amRNSUpdate regarding Silicon Valley Bank
1st Mar 20231:57 pmRNSPDMR Shareholding/Share Incentive Plan
30th Jan 20235:11 pmRNSPDMR Shareholding/Share Incentive Plan
26th Jan 20237:00 amRNSUSD 7m enterprise engagements for data services
26th Jan 20237:00 amRNSTrading Statement and Strategy Update
3rd Jan 20237:00 amRNSPDMR Shareholding/Share Incentive Plan
29th Nov 20227:00 amRNSChange of Auditor
29th Nov 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
1st Nov 20227:00 amRNSSub-optimal testing impacts on cancer patients
31st Oct 20222:20 pmRNSPDMR Shareholding/Share Incentive Plan
5th Oct 20225:03 pmRNSPDMR Shareholding/Share Incentive Plan
5th Oct 20227:00 amRNSPurchase of Shares and PDMR Shareholding
27th Sep 20227:00 amRNSHalf-year Report
12th Sep 202212:38 pmRNSPDMR Shareholding/Share Incentive Plan
8th Sep 20227:00 amRNSNotice of Results and Presentations
8th Aug 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
26th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Jul 20225:45 pmRNSPDMR Shareholding/Share Incentive Plan
13th Jun 20227:00 amRNSMulti-year contract with top five global pharma
7th Jun 20227:00 amRNSNew AI and ML Capabilities Enhance DXRX Platform
31st May 202212:12 pmRNSPDMR Shareholding/Share Incentive Plan
27th May 20224:31 pmRNSShare Options and PDMR Shareholdings
26th May 20223:00 pmRNSResult of AGM
11th May 20222:34 pmRNSPDMR Shareholding/Share Incentive Plan
9th May 20224:37 pmRNSExercise of Warrant & Total Voting Rights
5th May 20227:00 amRNSContract Win
29th Apr 20225:22 pmRNSPDMR Shareholding/Share Incentive Plan
28th Apr 20222:09 pmRNSNotice of AGM and Posting of Annual Report
7th Apr 20227:00 amRNSPurchase and Sale of Shares and PDMR Shareholdings
6th Apr 20221:13 pmRNSPDMR Shareholding/Share Incentive Plan
5th Apr 20223:49 pmRNSConversion of Convertible Loan Notes & TVR
1st Apr 20227:00 amRNSIssue of Share Options / PDMR Shareholdings
31st Mar 20225:38 pmRNSPDMR Shareholding/Share Incentive Plan
22nd Mar 20222:43 pmRNSFinal Results
22nd Mar 20227:00 amRNSNotice of 2021 Full Year Results
18th Mar 20222:09 pmRNSConfirmation of Directorate Change
16th Mar 20225:49 pmRNSHolding(s) in Company
16th Mar 20227:00 amRNSApproval by CMS for enhanced data access
2nd Mar 20225:37 pmRNSPDMR Shareholding/Share Incentive Plan
21st Feb 20227:00 amRNSInvestor Presentation
14th Feb 20226:26 pmRNSPDMR Shareholding/Share Incentive Plan
14th Feb 20227:00 amRNSContract with leading life sciences company
4th Feb 202211:26 amRNSDirector/PDMR Shareholding
11th Jan 20227:01 amRNSDirectorate Change
11th Jan 20227:00 amRNSTrading Update and Notice of Results
4th Jan 20227:00 amRNSPDMR Shareholding/Share Incentive Plan
14th Dec 20217:00 amRNSContract Win
9th Dec 20217:00 amRNSTest Signal Launch and Contract Wins
1st Dec 20215:22 pmRNSPDMR Shareholding/Share Incentive Plan
9th Nov 20214:57 pmRNSPDMR Shareholding/Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.